TSHA
Research Snapshot
Static fundamentals, valuation context, and investor signals for Taysha Gene Therapies, Inc. (TSHA).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-44.1%
ROIC, -960.1% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 12.2x current ratio
Superinvestors
1
Top: Polen Capital Management (0.0%)
Strengths to research
- Debt/equity looks manageable at 0.0x.
Watchouts
- Free cash flow margin is negative at -960.1%.
- Valuation multiples are limited or unavailable.
Annual data: 6 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for TSHA.
Grade F
1
/ 100
Financial Charts
No financial data available for TSHA (annual).
1 superinvestors own TSHA
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 319,748 | $1M | 0.01% | 0.0% |